You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Danaher's life sciences revenues grew 6 percent, while its diagnostics revenues rose nearly 5 percent, including an increase of more than 20 percent at Cepheid.
The firm said that its molecular diagnostics sales growth in the quarter was negatively impacted by non-governmental organization purchasing patterns in Africa.
The San Diego-based firm said it expects second quarter revenues of $835 million, short of the average analyst estimate of $888 million.
Core revenues grew 4 percent year over year, but the firm missed Wall Street analyst estimates on both the top and bottom lines.
The firm said its growth was driven in part by increasing sales volumes of its gastrointestinal PancraGen business and endocrine ThyGeNext/ThyraMir business.
The liquid biopsy firm beat analyst estimates on the top and bottom lines and raised full-year revenue guidance to $145 to $150 million.
The company reported $26 million in total revenues for the quarter and said that testing services revenues more than doubled year over year.
The firm said that it placed about 50 sample-to-answer molecular systems under contract during Q1, and it had about 625 active sample-to-answer product customers.
Within diagnostics, molecular revenues were up 11 percent year over year to $167.8 million. The firm received two new CE marks for early infant diagnosis and testing dried blood spots.
For the quarter ended March 31, Twist reported $13.6 million in revenues, up from $6.2 million during the same period last year.
The Atlantic reports another SARS-CoV-2 testing problem may be lurking: backlogs.
Researchers have sequenced the genome of "the Methuselah of freshwater fish."
The US Biomedical Advanced Research and Development Authority is supporting efforts to develop vaccines against SARS-CoV-2.
In Genome Biology this week: difference in methylation in neurons from Parkinson's disease patients, differential expression analysis by barcoded sequencing approach, and more.